SCHEMBL6955048

SCHEMBL6955048

FC(F)(F)Oc1cccc(Oc2ccccc2CBr)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
CETP P11597 1/20 0.41
RIPK1 Q13546 1/20 0.41
SLC22A12 Q96S37 1/20 0.39
BRAF P15056 5/20 0.39
EPHX2 P34913 1/20 0.39
AR P10275 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6953833 0.85 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CETPRIPK1
SCHEMBL29427096 0.78 SLC6A3 (0.43) SLC6A2SLC6A4SLC6A3MAPTHTT
SCHEMBL121522 0.78 SLC6A3 (0.43) SLC6A2SLC6A4SLC6A3MAPTHTT
SCHEMBL4040101 0.78 PPARA (0.48) RIPK1ALDH1A1
SCHEMBL2909934 0.77 SLC6A3 (0.43) SLC6A2SLC6A4SLC6A3MAPTHTT
SCHEMBL31120714 0.76 GAA (0.58) SLC6A2SLC6A4SLC6A3BRAFALDH1A1
SCHEMBL9588339 0.76 AR (0.50) SLC6A2SLC6A4SLC6A3CETPBRAF
SCHEMBL4164702 0.76 CETP (0.56) CETP
SCHEMBL5536115 0.76 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3CETPSLC22A12
SCHEMBL561362 0.76 HRH1 (0.60) SLC6A2SLC6A4SLC6A3RIPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 SLC6A2 1098/4885SLC6A4 1209/4885SLC6A3 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.